Lyell Immunopharma, Inc. (LYEL) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial,...
Analysis Summary
Lyell Immunopharma, Inc. reported revenue of $36000 in the most recent fiscal year, growing at a 5-year CAGR of -65.9%.
Trailing-twelve-month margins: gross margin -85.4%, operating margin -7113.3%, net margin -9202.9%.
At the current price of $10.78, LYEL has negative trailing earnings (P/E not meaningful) and an ROE of -91.62%. Market capitalisation stands at $264M.
Balance sheet quality for LYEL: current ratio of 5.3, net cash position of $196.2M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $10.78 |
| Market Cap | $264M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.90 |
| EV / EBITDA | -1.08 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -91.62% |
| Return on Invested Capital | -70.80% |
| Return on Assets | -79.86% |
| Gross Margin | -8537.04% |
| Operating Margin | -711329.63% |
| Net Margin | -920285.19% |
Financial Health
| Debt / Equity | 0.16 |
| Current Ratio | 5.36 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.46 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LYEL | Lyell Immunopharma, Inc. | $264M | 0.90 | -91.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -31.73% |
| 3 months | -15.38% |
| Year-to-date | -64.98% |
| 1 year | -12.43% |
| 3 years | -66.73% |
| 5 years | -95.44% |
52-Week Range
| 52-week High | $45.00 |
| 52-week Low | $10.46 |
| Avg Volume (90d) | 159K |
Related companies: ACIU · ALDX · ALLO · AMRN · CABA · EDIT · GNLX
Explore sector: Healthcare · Biotechnology
More sections of LYEL: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks